Aligos Therapeutics, Inc.
ALGS
$10.01
$0.141.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.65M | 3.17M | 3.27M | 3.95M | 6.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.65M | 3.17M | 3.27M | 3.95M | 6.00M |
| Cost of Revenue | 68.45M | 61.28M | 68.41M | 70.27M | 76.50M |
| Gross Profit | -65.80M | -58.11M | -65.14M | -66.33M | -70.50M |
| SG&A Expenses | 20.93M | 20.40M | 21.22M | 22.83M | 23.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.38M | 81.68M | 89.62M | 93.10M | 99.86M |
| Operating Income | -86.73M | -78.50M | -86.35M | -89.15M | -93.86M |
| Income Before Tax | -86.15M | -73.84M | -52.91M | -130.88M | -76.68M |
| Income Tax Expenses | 311.00K | 346.00K | 350.00K | 331.00K | 274.00K |
| Earnings from Continuing Operations | -86.46 | -74.18 | -53.26 | -131.21 | -76.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.46M | -74.18M | -53.26M | -131.21M | -76.95M |
| EBIT | -86.73M | -78.50M | -86.35M | -89.15M | -93.86M |
| EBITDA | -85.82M | -77.56M | -85.41M | -88.13M | -92.68M |
| EPS Basic | -12.53 | -12.56 | -10.21 | -20.92 | -13.35 |
| Normalized Basic EPS | -7.81 | -7.82 | -6.35 | -13.04 | -8.23 |
| EPS Diluted | -19.76 | -19.79 | -17.45 | -20.92 | -13.35 |
| Normalized Diluted EPS | -7.92 | -7.93 | -6.46 | -13.04 | -8.23 |
| Average Basic Shares Outstanding | 35.41M | 31.31M | 27.22M | 25.06M | 23.85M |
| Average Diluted Shares Outstanding | 35.71M | 31.62M | 27.53M | 25.07M | 23.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |